ArticleInternational journal of clinical and experimental pathology2017
Soluble CD14 subtype (sCD14-ST) is a biomarker for neonatal sepsis.
Article in International journal of clinical and experimental pathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 3 syntheses or guidelines pooled it, 14 citations in OpenAlex.
- Presepsin as a diagnostic biomarker for sepsis across neonates, children, and adults: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Presepsin for the Diagnosis of Neonatal Early-Onset Sepsis: A Systematic Review and Meta-analysis.JAMA pediatrics · 2022Pooled it
- The diagnostic accuracy of presepsin in neonatal sepsis: a meta-analysis.European journal of pediatrics · 2018Pooled it
- The Role of I-FABP, REG3α, sCD14-ST, and LBP as Indicators of GI Tract Injury in MODS Patients.Diagnostics (Basel, Switzerland) · 2025Article
- Biomarkers of Neonatal Sepsis: Where We Are and Where We Are Going.Antibiotics (Basel, Switzerland) · 2023Review
- Can Presepsin Be Valuable in Reducing Unnecessary Antibiotic Exposure after Birth?Antibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This prospective observational study evaluated soluble CD14 subtype (sCD14-ST) as an early diagnosis and monitoring biomarker for neonatal sepsis in controls, patients with sepsis, or systemic inflammatory response syndrome (SIRS). sCD14-ST, procalcitonin (PCT), C-reactive protein (CRP), white blood cell (WBC), and acute physiology and chronic health evaluation II (APACHE-II) score were evaluated before and after therapy. sCD14-ST levels were significantly higher in sepsis than in SIRS, and higher in SIRS than controls. Treatment significantly decreased sCD14-ST, APACHE-II, PCT, CRP, and WBC. sCD14-ST levels correlated with APACHE-II before and after therapy, and with PCT before therapy (r=0.201, P=0.05). The receiver operating characteristic area under the curve of sCD14-ST was 0.958. A 304.5 pg/mL cutoff value was associated with 95.8% sensitivity and 84.9% specificity. sCD14-ST had superior diagnostic power for neonatal sepsis than the other indicators. In conclusion, sCD14-ST is a potential biomarker for the early diagnosis and monitoring of neonatal sepsis.
Indexed as
Identifiers
31966854PMC6965933W3007815940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.